IL166069A0 - CCK-1 receptor modulators - Google Patents

CCK-1 receptor modulators

Info

Publication number
IL166069A0
IL166069A0 IL16606904A IL16606904A IL166069A0 IL 166069 A0 IL166069 A0 IL 166069A0 IL 16606904 A IL16606904 A IL 16606904A IL 16606904 A IL16606904 A IL 16606904A IL 166069 A0 IL166069 A0 IL 166069A0
Authority
IL
Israel
Prior art keywords
cck
receptor modulators
modulators
receptor
Prior art date
Application number
IL16606904A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL166069A0 publication Critical patent/IL166069A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyridine Compounds (AREA)
IL16606904A 2002-07-03 2004-12-30 CCK-1 receptor modulators IL166069A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39349302P 2002-07-03 2002-07-03
PCT/US2003/020787 WO2004007463A1 (en) 2002-07-03 2003-07-02 Cck-1 receptor modulators

Publications (1)

Publication Number Publication Date
IL166069A0 true IL166069A0 (en) 2006-01-15

Family

ID=30115589

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16606904A IL166069A0 (en) 2002-07-03 2004-12-30 CCK-1 receptor modulators

Country Status (22)

Country Link
US (2) US7037931B2 (no)
EP (1) EP1525190A1 (no)
JP (1) JP2006501194A (no)
KR (1) KR20050042130A (no)
CN (1) CN100522947C (no)
AR (1) AR041183A1 (no)
AU (1) AU2003253776A1 (no)
BR (1) BR0312378A (no)
CA (1) CA2491213A1 (no)
CL (1) CL2003001360A1 (no)
CO (1) CO5400148A1 (no)
EA (1) EA009479B1 (no)
HR (1) HRP20041224A2 (no)
IL (1) IL166069A0 (no)
MX (1) MXPA05000204A (no)
NO (1) NO20050498L (no)
NZ (1) NZ537899A (no)
PL (1) PL374757A1 (no)
TW (1) TW200418469A (no)
UA (1) UA79804C2 (no)
WO (1) WO2004007463A1 (no)
ZA (1) ZA200500973B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79804C2 (en) * 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
RU2379292C2 (ru) 2003-04-18 2010-01-20 Мемори Фармасьютиклз Корпорейшн Производные пиразола в качестве ингибиторов фосфодиэстеразы 4
KR20060030506A (ko) * 2003-07-02 2006-04-10 얀센 파마슈티카 엔.브이. Ｃｃｋ-1 수용체 조절제
US20050020565A1 (en) * 2003-07-02 2005-01-27 Jones Todd K. CCK-1 receptor modulators
WO2005063716A1 (en) * 2003-12-22 2005-07-14 Janssen Pharmaceutica, N.V. Imidazoles and their use cck-1 receptor modulators
NZ551563A (en) * 2004-06-30 2009-06-26 Janssen Pharmaceutica Nv Alpha,beta-unsaturated esters and acids by stereoselective dehydration
CN101166733A (zh) 2004-10-15 2008-04-23 记忆药物公司 作为磷酸二酯酶4抑制剂的吡唑衍生物
US20060177438A1 (en) * 2005-02-08 2006-08-10 New England Medical Center Methods of altering absorption of hydrophobic compounds
CA2649927A1 (en) 2006-04-14 2007-10-25 Merck & Co., Inc. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
EP2010179B1 (en) * 2006-04-14 2010-07-07 Merck Sharp & Dohme Corp. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
JP5986098B2 (ja) * 2010-11-24 2016-09-06 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション インテグリン結合キナーゼ阻害剤
DK3071206T3 (da) 2013-11-22 2021-05-25 CL BioSciences LLC Gastrinantagonister (eg yf476, netazepid) til behandling og forebyggelse af osteoporose
CA2929785C (en) 2013-12-13 2018-02-13 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
WO2015086642A1 (en) 2013-12-13 2015-06-18 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826868A (en) 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US5164381A (en) 1986-05-29 1992-11-17 Ortho Pharmaceutical Corporation Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same
US5051518A (en) 1987-05-29 1991-09-24 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
AU611437B2 (en) * 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
ZA915372B (en) * 1990-07-17 1993-03-31 Lilly Co Eli Pyrazolidinone cck and gastrin antagonists and pharmaceutical formulations thereof
CA2167154A1 (en) * 1993-08-10 1995-02-16 Sarkis Barret Kalindjian Gastrin and cck receptor ligands
US5756529A (en) 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
JPH09151183A (ja) * 1995-12-01 1997-06-10 Yoshitomi Pharmaceut Ind Ltd チエニルアミド化合物
DE19621687A1 (de) 1996-05-30 1997-12-04 Bayer Ag Verfahren zur Herstellung von substituierten Arylpyrazolen
DE60103136T2 (de) 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
GB0011095D0 (en) 2000-05-08 2000-06-28 Black James Foundation astrin and cholecystokinin receptor ligands (III)
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
GB0016787D0 (en) * 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
ATE455785T1 (de) * 2000-11-02 2010-02-15 Ajinomoto Kk Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
US6784185B2 (en) * 2001-03-16 2004-08-31 Pfizer Inc. Pharmaceutically active compounds
WO2002092576A1 (en) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
WO2003011854A1 (en) * 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
JP4357295B2 (ja) * 2001-08-03 2009-11-04 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾール誘導キナーゼインヒビターとその使用
WO2003024958A2 (en) 2001-09-18 2003-03-27 Onconova Therapeutics, Inc. Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
EP1438293A2 (en) * 2001-09-19 2004-07-21 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
WO2003037336A1 (en) * 2001-11-02 2003-05-08 Pfizer Products Inc. 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
EP1551794A4 (en) * 2002-06-19 2006-05-17 Bristol Myers Squibb Co UREIDO-SUBSTITUTED ANILINE COMPOUNDS SUITABLE AS SERINPROTEASE INHIBITORS
UA79804C2 (en) * 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators

Also Published As

Publication number Publication date
PL374757A1 (en) 2005-10-31
US20040067983A1 (en) 2004-04-08
CL2003001360A1 (es) 2005-06-03
EP1525190A1 (en) 2005-04-27
US7465808B2 (en) 2008-12-16
NO20050498L (no) 2005-03-16
UA79804C2 (en) 2007-07-25
NZ537899A (en) 2007-04-27
CO5400148A1 (es) 2004-05-31
EA009479B1 (ru) 2008-02-28
KR20050042130A (ko) 2005-05-04
CN1678587A (zh) 2005-10-05
US7037931B2 (en) 2006-05-02
AR041183A1 (es) 2005-05-04
EA200401621A1 (ru) 2005-06-30
JP2006501194A (ja) 2006-01-12
MXPA05000204A (es) 2005-09-30
WO2004007463A1 (en) 2004-01-22
AU2003253776A1 (en) 2004-02-02
TW200418469A (en) 2004-10-01
CA2491213A1 (en) 2004-01-22
BR0312378A (pt) 2005-04-26
US20060014817A1 (en) 2006-01-19
ZA200500973B (en) 2006-04-26
CN100522947C (zh) 2009-08-05
HRP20041224A2 (en) 2007-03-31

Similar Documents

Publication Publication Date Title
GB2384570B (en) Modulators
TWI340738B (en) Modulators of the glucocorticoid receptor
AU2003290778A8 (en) Non-steroidal farnesoid x receptor modulators
EP1581217A4 (en) CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR
EP1553963A4 (en) NOVEL AGENTS MODULATING EPH RECEPTOR ACTIVITY
GB0400440D0 (en) Receptor modulators
HRP20130638T1 (en) Cannabinoid receptor modulator
AU2003245773A1 (en) Vanilloid receptor modulators
PL376438A1 (en) Calcium receptor modulating arylalkylamines
IL159594A0 (en) Adenosine a3 receptor modulators
EP1620453A4 (en) MODULATION OF GLUCAGON RECEPTOR EXPRESSION
PL375559A1 (en) Calcium receptor modulating agents
AU2003237492A1 (en) Urotensin ii receptor modulators
IL166069A0 (en) CCK-1 receptor modulators
EP1641493A4 (en) RADIOACTIVELY MARKED CANNABINOID-1 RECEPTOR MODULATORS
AU2002335075A1 (en) Estrogen receptor modulators
HK1070362A1 (en) Non-steroidal progesterone receptor modulators
IL172921A0 (en) Cck-1 receptor modulators
AU2003231523A1 (en) Estrogen receptor modulators
GB2386965B (en) Electro-optic modulators
EP1581309A4 (en) KINASE MODULATORS
IL173337A0 (en) Receptor
GB0306575D0 (en) Modulators
EP1467739A4 (en) 17-HYDROXY-4-AZA-ANDROSTAN-3-ONE AS ANDROGEN RECEPTOR MODULATORS
AU2003226396A8 (en) Imidazolidine compounds as chemokine receptor modulators